Clinical Trial Update: A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male Subjects [Phase 1]

View source ↗

Summary

Phase 1 single ascending dose study of BIA 9-1067 in healthy male subjects; Parkinson disease listed as a condition, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• BIA 9-1067

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Parkinson Disease | Phase 1 | Status: COMPLETED | Results posted: 2015-01-08